All In Biotech

Drug Trial Radar · NCT01712984

Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

Immunogenicity and Safety Trial of Quadrivalent Influenza Vaccine Administered by Intradermal Route in Adult Subjects Aged 18 Through 64 Years

Last checked: Nov 19, 2026Latest source record: May 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,360 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,360

Actual

Start

Oct 2012

Primary completion

Jun 2013

Study completion Oct 2013

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Oct 24, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of the study is to demonstrate safety and immunogenicity of the quadrivalent influenza intradermal (QIV-ID) vaccine compared to the trivalent influenza vaccine (TIV) containing the B strain from the primary (Yamagata) lineage (TIV-ID1) and the trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage (TIV-ID2) vaccines in producing protection against four strains of influenza virus. Primary Objective: * To demonstrate that QIV-ID induces an immune response (as assessed by hemagglutination inhibition (HAI) geometric mean titers (GMTs) and seroconversion rates) that is non-inferior to responses induced by TIV-ID1 and TIV-ID2 for the 4 virus strains at 28 days post-vaccination. Secondary Objectives: * To demonstrate that each B strain in QIV-ID induces an immune response (as assessed by HAI GMTs and seroconversion rates) that is superior to the response induced by the TIV-ID that does not contain the corresponding B strain. * To describe the rate of post-vaccination seroprotection induced by QIV-ID and TIV-ID. * To describe post-vaccination immunogenicity stratified by age (18-49 years and 50-64 years), race, ethnicity, gender, previous vaccination status, and baseline seropositivity status. * To describe the safety profile for subjects who receive QIV-ID and TIV-ID. Observational Objectives: * To demonstrate non-inferiority of QIV-ID compared to TIV-ID in terms of all Grade 2 or Grade 3 solicited systemic reactions combined * To demonstrate non-inferiority of QIV-ID compared to TIV-ID in terms of all Grade 3 solicited injection site reactions combined.

Conditions

  • Influenza

Interventions

  • Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 FormulationBiological

    0.1mL, Intradermal

  • Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® IntradermalBiological

    0.1mL, Intradermal

  • Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone IntradermalBiological

    0.1mL, Intradermal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Titers Against the Influenza Virus Antigens Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal RouteTime frame: Day 28 post-vaccination
  2. Number of Participants With Seroconversion to Influenza Virus Vaccine Antigens Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal RouteTime frame: Day 28 post-vaccination

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Hoover, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Chandler, Arizona

  • Site not named

    Mesa, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Chula Vista, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Milford, Connecticut

  • Site not named

    Coral Gables, Florida

  • Site not named

    Melbourne, Florida

  • Site not named

    Pinellas Park, Florida

  • Site not named

    South Miami, Florida

  • Site not named

    Boise, Idaho

  • Site not named

    Iowa City, Iowa

  • Site not named

    Overland Park, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Kansas City, Missouri

  • Site not named

    Springfield, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Binghamton, New York

  • Site not named

    Rochester, New York

  • Site not named

    Rochester, New York

  • Site not named

    Allentown, Pennsylvania

  • Site not named

    Bensalem, Pennsylvania

  • Site not named

    Warwick, Rhode Island

  • Site not named

    Mt. Pleasant, South Carolina

  • Site not named

    Dakota Dunes, South Dakota

  • Site not named

    Austin, Texas

  • Site not named

    Fort Worth, Texas

  • Site not named

    Fort Worth, Texas

  • Site not named

    San Angelo, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Salt Lake City, Utah

  • Site not named

    West Jordan, Utah

  • Site not named

    Marshfield, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.